media,
Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts..

The HIV Market will Grow Moderately Driven by Decreased Mortality and Increased Usage; Growth Will be Impacted by Patent Expiries

The HIV market is a growing market dominated by the US. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiry of key drugs. However, migration to new branded drugs is likely to minimize the impact of generics, which currently account for approximately 8% of the market. The global HIV therapeutics market is expected to grow at a CAGR of 4.5% from $13 billion in 2008 and to $17 billion in 2016. The market is driven by an increase in the treatment-seeking rate as well as the introduction of newer drugs such as Atripla as part of HAART. The HIV market is growing at a slower rate compared to previous years. This is primarily due to the patent expiry of major drugs such as Sustiva and Combivir in 2012. Some other drugs such as Epivir, Epzicom, Trizivir, Ziagen, Invirase and Lexiva are going off patent in 2009 and 2010. However the impact of patent expiration will be offset by the increased use of newer drugs which are more effective in tackling the progression of the disease.

The sales of new drugs such as Atripla have increased by a CAGR of 136% over the last three years; other drugs such as Trizivir, Relenza and Epivir have declined by a CAGR of 11%, 21% and 17% respectively. Approximately 1.5 million people infected with HIV received antiretroviral treatment (ART) in 2008 for an average cost of therapy of $8,300 per year. The number of people taking treatment for HIV is increasing at a slow rate of 2.2% per year. In addition, the average annual cost of therapy for ART is forecast to increase at a higher rate over the next 3-4 years with an expected price decline in 2013 onwards due to a series of patent expirations. However, the market is again expected to increase slightly towards the end of 2016 due to a shift to newer drugs as well as the impact of inflation. Additionally, the late stage pipeline drugs such as Rilpivirine by Tibotec Pharmaceuticals and Vicriviroc by Schering-Plough are expected to enter market during 2009-2016 and will positively impact the market. As a result, the HIV market value is going to see a moderate increase over the time period 2009-2016.

This article was prepared by NewsRx editors from staff and other reports.